

February 14, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Outcome of the Board Meeting held on 14th February, 2025

Pursuant to Regulations 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, 14th February 2025, have approved the following agendas:

1. Appointment of Mr. Pradeep Kumar Sinha (DIN: 00145126) as an Additional Director designated as Non-Executive – Independent Director of the Company:

Based on the recommendation of the Nomination and Remuneration Committee, the Board of the Company at its Meeting held today has approved the appointment of Mr. Pradeep Kumar Sinha (DIN: 00145126) as an Additional Director designated as Non-Executive - Independent, not liable to retire by rotation, effective today i.e. February 14, 2025.

Pursuant to the BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/24 dated June 20, 2018, Mr. Pradeep Kumar Sinha is not debarred from holding the office of Director by virtue of any order of the Securities and Exchange Board of India or any other such authority.

The Company shall seek the approval of Shareholders through Postal Ballot.

Details in respect of the said appointment are enclosed herewith as **Annexure A**.

2. Re-appointment of Mr. Rajesh Desai (DIN: 00007960) and Mr. Dipankar Bhattacharjee (DIN: 08770548) as Non-Executive Independent Directors of the Company:

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at its meeting held today, has approved the re-appointment of Mr. Rajesh Desai (DIN: 00007960) as Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th June, 2025 and Mr. Dipankar Bhattacharjee (DIN: 08770548) as Non-Executive Independent Director of the Company for a further period of 5 years with effect from 14th August, 2025.

Further, this is to confirm that Mr. Rajesh Desai and Mr. Dipankar Bhattacharjee, Non- Executive Independent Directors of the Company are not debarred from holding the office pursuant to any SEBI order or any such authority respectively.

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

The Company shall seek the approval of Shareholders through Postal Ballot.

Details in respect of the said appointment are enclosed herewith as **Annexure A**.

3. Reconstitution of Board Committees:

Consequent to the aforesaid appointment, the following committees of the Board have been re-constituted as under:

Sr. No.	Committees of the Board	Composition of the Committees with effect from 15th February, 2025
1.	Audit Committee	Mrs. Vijayalakshmi Iyer – Chairman Mr. Rajesh V. Desai - Member Ms. Saira Ramasastry - Member
2.	Risk Management Committee	Mr. Dipankar Bhattacharjee– Chairman Mr. Rajesh V. Desai – Member Mr. Glenn Saldanha – Member Mr. V.S. Mani – Member
3.	Corporate Social Responsibility Committee	Mrs. Cherylann Pinto - Chairperson Mrs. Vijayalakshmi Iyer - Member Mr. Pradeep Kumar Sinha – Member
4.	ESG (Environment Social and Governance) Committee	Mr. Glenn Saldanha – Chairperson Mr. Dipankar Bhattacharjee – Member Ms. Sona Saira Ramasastry – Member Mr. Pradeep Kumar Sinha – Member

The said Board Meeting commenced at 02:00 p.m. and ended at 04:25 p.m.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber

Company Secretary & Compliance Officer

Encl: As above

Annexure A

Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

Sr. No.	Particulars	Details		
1.	Name of the Director	Mr. Pradeep Kumar Sinha	Mr. Rajesh Desai	Mr. Dipankar Bhattacharjee
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment	Re-appointment	Re-appointment
3.	Date of appointment/ cessation (as applicable) & term of appointment;	Based on the recommendations of the Nomination and Remuneration Committee, the Board of the Company considered and approved the appointment of Mr. Pradeep Kumar Sinha (DIN: 00145126) as an Additional Director designated as Non-Executive Independent Director, subject to approval of the shareholders of the Company for a term of 5 (five) years with effect from February 14, 2025 up to February 13, 2030 (both days inclusive).	Effective date of re-appointment – For a second term of 5 (Five) years commencing from June 26, 2025 up to June 25, 2030	Effective date of re-appointment - For a second term of 5 (Five) years commencing from August 14, 2025 up to August 13, 2030
4.	Brief profile (in case of appointment);	Mr. Pradeep Kumar Sinha joined the Indian Administrative Service in 1977 after completing his Masters in Economics from the Delhi School of Economics in 1976. He had graduated in Economics (Honours) from St. Stephens College, Delhi. While in service, he completed	Mr. Rajesh Desai is a Chartered Accountant with over 38 years of rich experience. He was the Executive Director and Chief Financial Officer of Glenmark until 2016. Mr. Desai led the Finance, Legal and IT	Mr. Dipankar Bhattacharjee has over three decades of global experience leading healthcare businesses across North America, Europe, APAC and MEA. Mr. Bhattacharjee was President & CEO – Global Generics

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

		<p>M. Phil in Social Sciences in 1991 and was a Visiting Fellow in University of Oxford during 1999. He has also attended prestigious programmes, such as, on 'Mergers and Acquisitions' in University of Stanford and on 'Leaders in Development' in Harvard University.</p> <p>In the formative years, he served in the State of Uttar Pradesh, thereafter he served mostly in the Government of India and rose to the highest position of Cabinet Secretary, the head of civil services. He served as the Cabinet Secretary for more than 4 years before moving to the Prime Minister's Office. He retired from there in March 2021 after 44 years of continuous service to the nation.</p> <p>In the Govt. of India, he worked mostly in the Power and Oil & Gas (Petroleum) Ministries for about 15 years. Notable positions held in Gov't of India include: Financial Advisor and Special Secretary, Petroleum and Natural Gas; Secretary, Ports and Shipping; and Secretary, Power.</p>	<p>functions at Glenmark, and has contributed significantly to its growth story.</p> <p>Mr. Rajesh Desai was appointed as an Independent Director at Company's Annual General Meeting held on September 29, 2020 for a period of 5 (Five) years starting from June 26, 2020 to June 25, 2025.</p>	<p>Medicines at Teva Pharmaceutical Industries, and prior to that, he held senior leadership roles at Bausch & Lomb, Bank of America, and Nestlé. He currently advises investors on mergers and acquisitions in the European generics space.</p> <p>Mr. Dipankar Bhattacharjee was appointed as an Independent Director in Company's Annual General Meeting held on September 29, 2020 for a period of 5 (Five) years starting from August 14, 2020 to August 13, 2025.</p>
--	--	--	---	---

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

		<p>He was a Government Nominee Director in numerous major Public Sector Undertakings and is therefore well versed with the principles of healthy corporate governance. These include ONGC, IOCL, HPCL, BPCL, GAIL, etc. In particular, he was on the Board of Indian Oil Corporation (IOCL) for about 7 years at a stretch and similarly on the Boards of BPCL and HPCL for about 6 years each.</p> <p>Mr. Pradeep Kumar Sinha is a Non-Executive Chairman of ICICI bank Limited and also Chairman of CSR Committee and a member of Nomination Remuneration Committee and Risk Committee.</p>		
5.	Disclosure of relationships between directors (in case of appointment of a director)	None	None	None

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com